In vitro, miR-193b interfered with cell-cycle progression, differentiation and viability of leukemia cell lines and primary AML samples, by targeting key regulators of MAPK signaling (KIT, KRAS, SOS2) and CCND1 (119, 120). Here, KIT is linked to acute myeloid leukemia.